Markers of Estimation of Efficiency of Treatment of Patients with Chronic Generalized Periodontitis Associated by Metabolic Syndrome
DOI : 10.36344/ccijmb.2019.v01i03.001 | Cross Current Int J Med Biosci, 2019; 1(3): 51-54
Downloads : 6 | Views : 8
Abstract: The purpose of this study was to increase the effectiveness of treatment of chronic generalized periodontitis in patients with metabolic syndrome on the basis of studying clinical and laboratory parallels of the biochemical status of the oral cavity. 52 patients with CGP combined with MS were examined. At the age of 20-60 years, and also 14 people - practically healthy people of the same age. For the study were formed 2 groups of patients, each of which consisted of 26 people. Depending on various treatment methods, patients were randomly randomized to the following groups: group 1 - patients with chronic hepatitis C combined with MS, receiving standard treatment for periodontal disease using Timogil gel and Trinomy, 2 groups, and (comparison group) - patients receiving standard treatment of CGP. The diagnosis of MS was established by cardiologists on the basis of a comprehensive clinical and laboratory examination. The high efficacy of the proposed therapeutic and prophylactic complex in relation to impaired levels of triglycerides, cholesterol and glucose in the oral fluid of CGP patients with concomitant MS has been shown. The biochemical studies of the roto fluid of the observed patients with chronic generalized periodontitis indicated a lack of basic therapy in the treatment and prevention of complications of periodontal tissue diseases against the background of MS, and also confirmed the established high efficacy of the developed therapeutic and preventive complex.
Patient Behavior: An Extensive Review
Abdul Kader Mohiuddin
DOI : 10.36344/ccijmb.2019.v01i03.002 | Cross Current Int J Med Biosci, 2019; 1(3): 55-72
Downloads : 0 | Views : 0
Abstract: The most frequent causes of death in the United States and globally are chronic diseases, including heart disease, cancer, lung diseases, and diabetes. Behavioral factors, particularly tobacco use, diet and activity patterns, alcohol consumption, sexual behavior, and avoidable injuries are among the most prominent contributors to mortality. Projections of the global burden of disease for the next two decades include increases in noncommunicable diseases, high rates of tobacco-related deaths, and a dramatic rise in deaths from HIV/AIDS. Worldwide, the major causes of death by 2030 are expected to be HIV/AIDS, depressive disorders, and heart disease. At the same time, in many parts of the world, infectious diseases continue to pose grim threats, especially for the very young, the old, and those with compromised immune systems. Malaria, diarrheal diseases, and other infectious diseases, in addition to AIDS, are major health threats to the poorest people around the world. And, like chronic diseases, their trajectory may be influenced by the application of effective health behavior interventions. Substantial suffering, premature mortality, and medical costs can be avoided by positive changes in behavior at multiple levels. Most recently, there has been a renewed focus on public health infrastructure to plan for emergencies, including both human-made and natural disasters. During the past twenty years, there has been a dramatic increase in public, private, and professional interest in preventing disability and death through changes in lifestyle and participation in screening programs. Much of this interest in disease prevention and early detection has been stimulated by the epidemiological transition from infectious to chronic diseases as leading causes of death, the aging of the population, rapidly escalating health care costs, and data linking individual behaviors to increased risk of morbidity and mortality.